City of Seattle became first in nation with fire department EMTs administering buprenorphine medication in the field
Oct. 9, 2024, the Seattle Fire Department (SFD) expanded its Buprenorphine Pilot Program and Seattle became the first…
FDA approved first test to help identify elevated risk of developing opioid use disorder
On Dec. 19, 2023, the U.S. Food and Drug Administration approved the first test that uses DNA in…
Emergentsï¾’ NARCANï¾® Nasal Spray launched OTC making it possible for everyone to help save a life from an opioid overdose Emergency
On Aug. 30, 2023, Emergent BioSolutions announced NARCANï¾® Naloxone HCl Nasal Spray 4 mg would be available on…
Only 1 in 5 U.S. adults with opioid use disorder received medications to treat it in 2021
On Aug. 7, 2023, a National Institute of Health supported study found that in 2021, an estimated 2.5…
U.S. FDA approved second OTC Naloxone nasal spray product
On Jul. 28, 2023, the U.S. FDA approved RiVive, 3 milligram (mg) naloxone hydrochloride nasal spray for over-the-counter…
U.S. FDA approved new buprenorphine treatment option for opioid use disorder
On May 24, 2023, the U.S. FDA approved Braeburn pharmaceutical’s Brixadi (buprenorphine) extended-release injection for subcutaneous use (under…
U.S. FDA approved first Over-the-Counter Naloxone nasal spray
On Mar. 29, 2023, the U.S. FDA announced approval of Narcan, 4 milligram naloxone hydrochloride nasal spray for…
Amphastar Pharmaceuticals received FDA approval for Naloxone hydrochloride nasal spray
On Mar. 8, 2023, Amphastar Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) had granted approval…
FDA approved naloxone injection to counteract opioid overdoses
On Oct. 18, 2021, the Food and Drug Administration approved ZIMHI (naloxone hydrochloride) injection as an additional option…
Bankruptcy judge approved federal settlement with Purdue Pharma
On Nov. 17, 2020, the proposed settlements between the federal government and OxyContin maker Purdue Pharma and its…
Purdue Pharma reached agreement with US Department of Justice
On Oct. 21, 2020, Purdue Pharma announced that it had entered into an agreement with the U.S. Department…
Penn Medicine received $22 million from NIH HEAL Initiative to combat the national opioid crisis
On Oct. 4, 2019, Penn Medicine announced they had received $22 Million from National Institutes of Health’s (NIH)…
Purdue Pharma announced Chapter 11 bankruptcy and preliminary agreement to settle opioid litigation
On Sept. 15, 2019, Purdue Pharma filed for Chapter 11 bankruptcy and announced that it had reached an…
AcelRx pharmaceutical DSUVIA was approved by FDA
On Nov. 2, 2018, AcelRx pharmaceutical’s DSUVIA was approved by U.S. Food and Drug Administration (FDA). DSUVIA is…
Dr. Horace H. Loh received the SCBA Lifetime Achievement Award for his achievements and leadership in biochemical neuropharmacology
In 2015, Dr. Horace H. Loh received the Society of Chinese Bioscientists in America (SCBA) Lifetime Achievement Award…
Cody Laboratories became one of only seven companies in the U.S. granted import license for raw opiate material
On Apr. 12, 2007, Cody Labs became one of only seven companies in the U.S. to be granted…
Stanford Medicine researchers discovered dynorphin, a brain chemical 200 times more powerful than morphine
On Dec. 21, 1979, Stanford Medicine pharmacologist Avram Goldstein announced the discovery of dynorphin – a chemical in…
The Harrison Narcotic Act required prescriptions for products exceeding the allowable limit of narcotics
On Feb. 14, 1924, the Harrison Narcotic Act required prescriptions for products exceeding the allowable limit of narcotics…